Global Ischemia Reperfusion Injury Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

PUBLISHED: June 1, 2023

PAGES: 180 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

The global demand for Ischemia Reperfusion Injury Therapeutics Market is presumed to reach the market size of nearly USD 8.55 BN by 2030 from USD 5.52 BN in 2022 with a CAGR of 5.62% under the study period 2023 - 2030.

Ischemia-reperfusion injury (IRI) therapeutics refer to the medical treatments and interventions used to prevent or treat tissue damage that occurs when blood flow is temporarily interrupted and then restored, known as ischemia-reperfusion injury. Ischemia-reperfusion injury can occur in various medical conditions such as stroke, myocardial infarction, organ transplantation, and traumatic injury. When blood flow is interrupted, tissues are deprived of oxygen and nutrients, leading to damage and cell death. When blood flow is restored, the resulting reperfusion can also cause tissue damage and inflammation. IRI therapeutics aim to prevent or mitigate this damage by reducing inflammation, promoting tissue repair, and protecting against oxidative stress. Some potential therapies for IRI include anti-inflammatory drugs, antioxidants, stem cell therapies, and gene therapies. Research into IRI therapeutics is ongoing, with the goal of developing new treatments and interventions to improve outcomes for patients with conditions such as stroke, heart attack, and organ transplantation. The ultimate goal of IRI therapeutics is to reduce the extent of tissue damage and promote tissue repair, leading to better clinical outcomes for patients.

Market Dynamics:

The incidence of conditions such as stroke, heart attack, and organ transplantation is increasing due to factors such as ageing populations and lifestyle issues such as inadequate diet and lack of exercise. This has led to a growing need for effective treatments for IRI. Advances in medical research have led to a better understanding of the mechanisms behind IRI and the development of new treatments and interventions. This has driven the growth of the IRI therapeutics market as new drugs and therapies are developed and tested. The importance of timely and effective treatment for IRI is becoming more widely recognized, leading to increased demand for IRI therapeutics. In many cases, timely treatment can be the difference between life and death, making IRI therapeutics a critical area of focus for the medical industry. Governments around the world are investing in medical research and initiatives aimed at improving outcomes for patients with conditions that can lead to IRI, including funding for clinical trials and research of new IRI therapeutics. Technological development of new IRI therapeutics, such as gene therapies and stem cell therapies, has the potential to provide more effective and targeted treatments for IRI, driving the growth of the IRI therapeutics market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of ischemia reperfusion injury therapeutics. The growth and trends of ischemia reperfusion injury therapeutics industry provide a holistic approach to this study.

Market Segmentation:

This section of the ischemia reperfusion injury therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

Drug Therapy
Medicated Gases
Others

By Injury

Heart Injury
Kidney Injury
Intestine Injury
Others

By End-User

Hospitals
Speciality Clinics
Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Ischemia Reperfusion Injury Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the ischemia reperfusion injury therapeutics market include Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology Inc., Opsona Therapeutics Limited, Pharming Group N.V., Prolong Pharmaceuticals, Prothix BV, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Faraday Pharmaceuticals, SBI Pharmaceuticals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR112110667

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ISCHEMIA REPERFUSION INJURY THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment
- 3.7.2 Market Attractiveness Analysis By Injury
- 3.7.3 Market Attractiveness Analysis By End-User
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ISCHEMIA REPERFUSION INJURY THERAPEUTICS MARKET ANALYSIS BY TREATMENT

6.1 Overview by Treatment
6.2 Historical and Forecast Data
6.3 Analysis by Treatment
6.4 Drug Therapy Historic and Forecast Sales by Regions
6.5 Medicated Gases Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL ISCHEMIA REPERFUSION INJURY THERAPEUTICS MARKET ANALYSIS BY INJURY

7.1 Overview by Injury
7.2 Historical and Forecast Data
7.3 Analysis by Injury
7.4 Heart Injury Historic and Forecast Sales by Regions
7.5 Kidney Injury Historic and Forecast Sales by Regions
7.6 Intestine Injury Historic and Forecast Sales by Regions
7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL ISCHEMIA REPERFUSION INJURY THERAPEUTICS MARKET SALES ANALYSIS BY END-USER

8.1 Overview by End-User
8.2 Historical and Forecast Data
8.3 Analysis by End-User
8.4 Hospitals Historic and Forecast Sales by Regions
8.5 Speciality Clinics Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL ISCHEMIA REPERFUSION INJURY THERAPEUTICS MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE ISCHEMIA REPERFUSION INJURY THERAPEUTICS COMPANIES

10.1. Ischemia Reperfusion Injury Therapeutics Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF ISCHEMIA REPERFUSION INJURY THERAPEUTICS INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Amyndas Pharmaceuticals LLC
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Angion
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Bolder Biotechnology Inc.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Opsona Therapeutics Limited
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Pharming Group N.V.
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Prolong Pharmaceuticals
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Prothix BV
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Stealth BioTherapeutics Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Zealand Pharma A/S
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Faraday Pharmaceuticals
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. SBI Pharmaceuticals.
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

Product Code: VMR112110667

LIST OF TABLES

Market Snapshot
Drivers : Impact Analysis
Restraints : Impact Analysis
List of Raw Material
List of Raw Material Manufactures
List of Potential Buyers
Analysis by Treatment (USD MN)
Drug Therapy Market Sales by Geography (USD MN)
Medicated Gases Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Analysis Market by Injury (USD MN)
Heart Injury Market Sales by Geography (USD MN)
Kidney Injury Market Sales by Geography (USD MN)
Intestine Injury Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Analysis by End-User (USD MN)
Hospitals Market Sales by Geography (USD MN)
Speciality Clinics Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Ischemia Reperfusion Injury Therapeutics Market Sales by Geography (USD MN)
North America Market Analysis (USD MN)
United State Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate by Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition